前瞻性随机AATT研究(外周T细胞淋巴瘤患者自体或异基因移植)的长期随访
Ⅲ期随机AATT研究长期随访显示,年轻外周T细胞淋巴瘤患者中,随机分配至异基因移植(alloSCT)者7年无事件生存率为38%(95%CI 25-52),随机分配至自体移植(autoSCT)者为34%(95%CI 22-47),总生存率分别为55%(95%CI 41-69)和61%(95%CI 47-74)。实际接受alloSCT者累积进展/复发率为8%(95%CI 0-19),接受autoSCT者为55%(95%CI 35-74)。alloSCT具有强烈的移植物抗淋巴瘤效应,独立于移植时机。
要点
- 随机分配至alloSCT者7年EFS为38%(95%CI 25-52),随机分配至autoSCT者为34%(95%CI 22-47)。
- 随机分配至alloSCT者7年OS为55%(95%CI 41-69),随机分配至autoSCT者为61%(95%CI 47-74)。
- 实际接受alloSCT者累积进展/复发率为8%(95%CI 0-19),接受autoSCT者为55%(95%CI 35-74)。
核心结论
- 长期随访证实alloSCT具有强烈的移植物抗淋巴瘤效应,独立于移植时机。
- 无法接受移植的患者生存极差。
- AlloSCT是年轻、适合移植的复发/难治性PTCL患者的治疗选择。
- AlloSCT目前不推荐作为一线巩固治疗的一部分。
研究设计与样本
- Ⅲ期随机AATT研究,比较年轻外周T细胞淋巴瘤患者接受alloSCT或autoSCT巩固治疗的疗效。
主要发现
- 随机分配至alloSCT者7年EFS为38%(95%CI 25-52),随机分配至autoSCT者为34%(95%CI 22-47)。
- 随机分配至alloSCT者7年OS为55%(95%CI 41-69),随机分配至autoSCT者为61%(95%CI 47-74)。
- 实际接受alloSCT者(n=26)累积进展/复发率为8%(95%CI 0-19),接受autoSCT者(n=41)为55%(95%CI 35-74)。
- alloSCT后非复发死亡率为31%(95%CI 13-49),autoSCT后为3%(95%CI 0-8)。
- 30例早期进展患者中15例、autoSCT后进展/复发20例患者中11例接受了alloSCT;挽救性alloSCT后7年OS为61%(95%CI 47-74),非复发死亡率为23%(95%CI 6-40)。
临床怎么用
- AlloSCT是年轻、适合移植的复发/难治性PTCL患者的治疗选择。
- AlloSCT目前不推荐作为一线巩固治疗的一部分。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Primary analysis of the phase III randomized AATT study showed that younger patients with peripheral T-cell lymphoma (PTCL) consolidated with autologous or allogeneic transplantation (alloSCT) had similar event-free survival (EFS) and overall survival (OS). Seven-year EFS of patients randomly assigned to alloSCT was 38% (95% CI, 25 to 52) compared with 34% (95% CI, 22 to 47) for patients randomly assigned to autologous transplantation of hematopoietic stem cells (autoSCT); OS was 55% (95% CI, 41 to 69) and 61% (95% CI, 47 to 74). Among patients undergoing alloSCT (n = 26) or autoSCT (n = 41) on study, the cumulative progression/relapse rate was 8% (95% CI, 0 to 19) and 55% (95% CI, 35 to 74). Nonrelapse mortality (NRM) was 31% (95% CI, 13 to 49) and 3% (95% CI, 0 to 8) after alloSCT and autoSCT, respectively. Fifteen of 30 patients with early progression and 11 of 20 patients with progression/relapse after autoSCT received alloSCT. Seven-year OS after salvage alloSCT was 61% (95% CI, 47 to 74); NRM was 23% (95% CI, 6 to 40). Long-term follow-up documents the strong graft versus lymphoma effect of alloSCT independent of the timing of transplantation. Survival of patients unable to undergo transplantation was dismal. AlloSCT is the treatment of choice for younger, transplant-eligible patients with relapsed/refractory PTCL. AlloSCT is currently not recommended as part of first-line consolidation.
引用
- Tournilhac O, Altmann B, Friedrichs B, et al. Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma). J Clin Oncol. 2024. PMID: 39270145. doi:10.1200/JCO.24.00554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。